Zheng Quan Shi Bao Wang·2025-09-02 05:58Core Viewpoint - The report from Citi highlights that Alibaba Health has raised its revenue growth guidance for the fiscal year 2026 to 10%-20% and adjusted net profit growth guidance to 20%-30%, primarily driven by better-than-expected sales performance of innovative drugs, particularly GLP-1 medications [1] Company Summary - Alibaba Health's strong sales data, along with that of JD Health, confirms the acceleration and sustainability of the trend of prescription drug outflow [1] - The online platforms are identified as the biggest beneficiaries for innovative pharmaceutical companies in expanding new sales channels [1] - Citi has revised its adjusted net profit forecasts for Alibaba Health for fiscal years 2026 and 2027 upwards by 8% and 12% respectively [1] - The target price for Alibaba Health has been increased from HKD 4.8 to HKD 6.5, while maintaining an "Outperform" rating [1]